To examine the management of Chronic Lymphocytic Leukemia (CLL) in India, focusing on the integration of global advances in treatment with local constraints.
Approach:
Epidemiology and Presentation: Discusses the incidence of CLL in India compared to the West, noting a lower incidence and younger age at presentation.
Diagnosis and Initial Work-up: Describes the diagnostic criteria for CLL and the limitations of diagnostic resources in India.
Key Findings:
CLL accounts for ~5% of leukemias in India, with an increasing incidence due to better awareness and diagnostics.
Indian patients present at a younger age and often at more advanced stages of disease compared to Western patients, although this may reflect referral bias and healthcare access issues.
Access to molecular profiling and targeted therapies is limited, affecting treatment decisions and options.
Bruton tyrosine kinase inhibitors (BTKi) and BCL-2 inhibitors show superior efficacy but face challenges in affordability and access, particularly in the context of Indian healthcare.
Interpretation:
The integration of advanced CLL treatments in India is challenged by economic and infrastructural factors, despite a trend towards earlier diagnosis and the adoption of precision medicine.
Limitations:
Data on CLL in India is primarily from tertiary referral centers, which may not represent the general population and could be influenced by referral bias and healthcare access barriers.
Limited access to molecular testing and targeted therapies affects treatment options and may lead to disparities in care.
Conclusion:
Improving access to molecular diagnostics and targeted agents, along with health-policy reforms, is essential to address disparities in CLL management between India and Western countries.
